Clinical Trial Update: Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

A comparative phase 2/3 trial evaluating docetaxel plus carboplatin versus epirubicin plus cyclophosphamide followed by docetaxel as adjuvant therapy in triple-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2, Phase 3 | Status: COMPLETED